文献速递外周动脉疾病

慢性肢体威胁性缺血术前静脉测绘中大隐静脉适用性与利用情况

Adequacy and utilization of greater saphenous vein in patients undergoing preoperative vein mapping for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2026-06-10

单中心回顾性分析349例慢性肢体威胁性缺血患者术前大隐静脉超声测绘,采用分层评分系统评估静脉适用性。结果显示67%患者大隐静脉至膝段适用,46%至小腿中段适用;超过半数旁路手术使用单段大隐静脉,结局与BEST-CLI试验一致。

要点

  • 术前静脉测绘显示67%患者大隐静脉至膝段适用,46%至小腿中段适用。
  • 大隐静脉至膝段A/B级与更优的一期通畅率相关。
  • 大隐静脉至膝段D/E级和拼接静脉是丧失一期通畅率的独立危险因素。

核心结论

  • 多数行术前静脉测绘的慢性肢体威胁性缺血患者拥有可用作旁路管道的大隐静脉。
  • 超过半数的腹股沟下旁路手术使用单段大隐静脉,结局与BEST-CLI试验一致。

研究设计与样本

  • 单中心回顾性分析,纳入2015至2025年行术前双功超声静脉测绘的慢性肢体威胁性缺血患者349例。
  • 采用标准化分层评分系统(A至E级)评估大隐静脉至膝段和小腿中段的适用性。

主要发现

  • 大隐静脉至膝段和至小腿中段最佳可用分级为适用(A/B)者分别占67%和46%,临界(C)占7.7%和13%,不适用(D/E)占25%和40%。
  • 共197条肢体行腹股沟下旁路,其中单段大隐静脉占53%,替代自体静脉占23%,人工血管占6.1%,冷冻保存静脉占18%。
  • 大隐静脉旁路中,至膝段分级A/B、C、D/E分别占81%、7.8%、11%;至小腿中段分别占57%、14%、29%。
  • 至膝段A/B级且行旁路者中69%使用单段大隐静脉,至小腿中段A/B级者中该比例为82%。
  • 大隐静脉旁路术后1年主要再干预率17%、主要截肢率10%、主要不良肢体事件率23%;至膝段D/E级和拼接静脉与一期通畅率丧失独立相关(风险比3.8,95%CI 1.8-7.8,P<.001;风险比2.1,95%CI 1.2-3.8,P=.01)。

关键数值与推荐

  • 大隐静脉分级标准:A级≥3 mm,B级≥2.5 mm,C级>2 mm,D级任何部分≤2 mm,E级血栓形成、消融、曲张或既往获取。
  • 至膝段A/B级与更优的一期通畅率相关(P<.001)。

临床怎么用

  • 术前静脉测绘可用于评估大隐静脉作为旁路管道的适用性,指导旁路手术规划。
  • 大隐静脉至膝段A/B级者优先考虑单段大隐静脉旁路,至膝段D/E级或需拼接静脉时需警惕通畅率下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Infrainguinal bypass (IB) using single-segment greater saphenous vein (ssGSV) demonstrates superior outcomes for chronic limb-threatening ischemia (CLTI), but the definition and prevalence of adequate ssGSV are not well established. METHODS: This is a single-center retrospective analysis of patients with CLTI who underwent preoperative vein mapping (VM) by duplex ultrasound (2015-2025). A standardized hierarchical scoring system was applied to classify GSV suitability as a bypass conduit, measured from the saphenofemoral junction to the knee (GSV-K) and to mid-calf (GSV-MC) (A: ≥3 mm, B: ≥2.5 mm, C: >2 mm, D: any portion ≤2 mm, and E: thrombosed, ablated, varicose, previously harvested). GSV quality, associated clinical factors, and interventions received were analyzed. Major adverse limb events (MALE) and patency were assessed as outcomes. RESULTS: Patients (n = 349) had a median age of 71.1 years, and 68% of the patients were male. Comorbidities included diabetes (67%), end-stage renal disease (13%), coronary revascularization (37%), heart failure (38%), and current tobacco use (22%). The best available GSV-K and GSV-MC were classified as adequate (A/B) in 67% and 46%, marginal (C) in 7.7% and 13%, and inadequate (D/E) in 25% and 40%, respectively. In this cohort, IB was performed on 197 limbs (representing 67% of all IB performed for CLTI during the study period), using ssGSV (53%), alternate autogenous vein (23%), prosthetic (6.1%), or cryopreserved vein (18%). Among GSV bypasses performed, 32% were femoropopliteal, 19% infrapopliteal, and 49% femorodistal. The GSV conduits used were classified by VM as GSV-K: 81% A/B, 7.8% C, and 11% D/E; and GSV-MC: 57% A/B, 14% C, and 29% D/E. Of limbs with grade A/B GSV-K that underwent bypass (n = 133), 69% used an ssGSV conduit; this utilization rose to 82% for grade A/B GSV-MC (n = 87). Major reintervention, major amputation, and MALEs at 1 year after GSV bypass (ss or spliced) were 17%, 10%, and 23%, respectively. Among GSV bypasses, preoperative grade A/B GSV-K was associated with superior primary patency (P < .001). In a Cox proportional hazards multiple regression model, GSV-K grade D/E and spliced GSV conduits were independently associated with loss of primary patency (hazard ratio, 3.8; 95% confidence interval, 1.8-7.8; P < .001 and hazard ratio, 2.1; 95% confidence interval, 1.2-3.8; P = .01, respectively). CONCLUSIONS: Most patients with CLTI undergoing preoperative VM had adequate GSV for use as a bypass conduit. More than half of IBs performed used an ssGSV conduit, with outcomes consistent with those observed in the Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Liu IH, Calthorpe LM, Flanagan CP, et al. Adequacy and utilization of greater saphenous vein in patients undergoing preoperative vein mapping for chronic limb-threatening ischemia. J Vasc Surg. 2026. PMID: 42269705. doi:10.1016/j.jvs.2026.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。